Last updated: February 23, 2026
What is NDC 72603-0233?
NDC 72603-0233 refers to Aflibercept (Eylea), an anti-vascular endothelial growth factor (VEGF) agent used primarily to treat age-related macular degeneration (AMD), diabetic macular edema (DME), and other retinal conditions. Manufactured by Regeneron Pharmaceuticals, Eylea is administered via intravitreal injection.
Market Overview
Market Size (2022-2027)
The global retinal disease therapeutics market valued at approximately USD 9 billion in 2022, is projected to reach USD 13 billion by 2027. Aflibercept's segment accounts for an estimated 40-45% of this market, driven by:
- Rising prevalence of AMD and DME.
- Improved awareness and diagnosis.
- Expansion in off-label indications.
Regional Market Dynamics
| Region |
Market Share (2022) |
Growth Rate (2022-2027) |
Key Factors |
| North America |
~45% |
8% |
High prevalence of AMD, reimbursement policies, R&D |
| Europe |
~25% |
7% |
Aging population, healthcare infrastructure |
| Asia-Pacific |
~20% |
10%+ |
Increasing tech adoption, rising diabetes rates |
| Rest of World |
~10% |
6-8% |
Limited access, market penetration challenges |
Competitor Landscape
Major competitors include:
- Ranibizumab (Lucentis) by Novartis
- Bevacizumab (Avastin) off-label use, lower price
- Faricimab (Roche), in late-stage trials
Eylea maintains market dominance with:
- Extended dosing intervals (monthly for initial, then every ~8 weeks)
- Strong brand recognition
- Extensive clinical data supporting efficacy
Price Analysis and Projections
Current Pricing (2023)
- U.S. Wholesale Acquisition Cost (WAC): Approximately USD 1,850 per injection.
- Average reimbursement: USD 1,500-1,750 per injection, depending on payer mix.
- Dosing frequency: Typical regimen involves 3-4 injections per year, slightly declining with extended intervals.
Cost Dynamics
- Cost per treatment course: Approx. USD 5,550-7,000 annually.
- Patient volume estimates: 2 million+ patients globally; U.S. market accounts for ~900,000 treated annually.
Price Trends (Next 3-5 Years)
| Year |
Predicted WAC Price |
Key Drivers |
| 2024 |
USD 1,800-1,900 |
Competitive pressures, biosimilar development, policy shifts |
| 2025 |
USD 1,750-1,850 |
Biosimilar entries, payer negotiations |
| 2026 |
USD 1,650-1,750 |
Increased biosimilar adoption, cost-cutting initiatives |
Biosimilar development presents a significant potential for price reductions. U.S. FDA-approved biosimilars or near-approvals could lower prices by 20-30%. European markets see similar trends, with some biosimilars priced 15-25% below reference.
Potential Impact of Biosimilars
- Decreased margins for patent holders.
- Increased access in emerging markets.
- Pressure on list prices in developed markets.
Key Market Drivers and Risks
Drivers
- Aging populations increase demand.
- New indications expand patient base.
- Clinical advantages over competitors (extended dosing).
Risks
- Biosimilar competition may erode pricing.
- Regulatory changes may impact reimbursement.
- Off-label use of cheaper alternatives affects Eylea's uptake.
Investment and R&D Outlook
- Regeneron plans to develop next-generation VEGF inhibitors.
- Compound pipeline includes longer-acting formulations.
- Focus on expanding into emerging markets.
Conclusions
Eylea (NDC 72603-0233) maintains market dominance due to clinical efficacy, dosing advantages, and robust manufacturing capacity. However, rising biosimilar competition and policy measures could halve current pricing levels over the next five years.
Key Takeaways
- Eylea holds approximately 45-50% of the retinal therapeutics market share.
- Current U.S. price per injection hovers near USD 1,850.
- Market is expected to grow at 7-10% annually until 2027.
- Biosimilar entries could reduce prices by 20-30% in developed markets.
- Strong demand driven by aging populations sustains revenue, despite competitive pressures.
FAQs
-
What factors influence Eylea’s pricing?
Reimbursement policies, biosimilar competition, geographic location, dosing regimen, and payer negotiations.
-
How critical is biosimilar entry for market prices?
Biosimilars can significantly lower prices, potentially reducing current costs by up to 30%, affecting revenue streams.
-
What markets have the greatest growth potential?
Asia-Pacific and emerging markets with increasing diabetes prevalence and aging populations.
-
Are there upcoming alternatives expected to affect Eylea’s market share?
Yes. Faricimab has shown promising clinical data. If approved widely, it could challenge Eylea’s dominance.
-
What is the outlook for future R&D investments?
Companies invest in longer-acting formulations and alternative delivery methods to extend patent life and capture unmet needs.
Sources
[1] MarketWatch. (2022). Retinal disease therapeutics market analysis.
[2] Regeneron Pharmaceuticals. (2023). Eylea prescribing information.
[3] EvaluatePharma. (2023). Biosimilar landscape and impact analysis.
[4] IQVIA. (2022). Global ophthalmology market report.
[5] FDA. (2022). Biosimilar approval summaries.
